News and press announcements

Interaction between pharmaceutical companies and medical professionals in COVID situation

May 12, 2020, Sofia

The Association of the Research-based Pharmaceutical Manufacturers (ARPharM) and its member companies are committed to the global fight against the COVID-19 pandemic due to coronavirus. Our thoughts are with the people affected by the infection and their loved ones, as well as with the doctors and pharmacists who are at the forefront in the fight to overcome the pandemic.

The Research-based pharmaceutical industry is focused on three key areas: • the development of new vaccines, diagnostics and drug therapies to combat COVID-19 - around 7 vaccine applicants and over 30 antiviral drugs at various stages of development or use are currently being investigated by innovative pharmaceutical companies in over 25 clinical trials to determine whether they are effective in preventing or treating patients with COVID-19 - http://arpharm.org/index.php?id=1245;

read more
Coronavirus – your questions answered

Q. What is a coronavirus? Coronaviruses are a large family of viruses which may cause illness in animals or humans. In humans, several coronaviruses are known to cause respiratory infections ranging from the common cold to more severe diseases such as Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS). The most recently discovered coronavirus causes coronavirus disease COVID-19.

COVID-19 is the infectious disease caused by the most recently discovered coronavirus. This new virus and disease were unknown before the outbreak began in Wuhan, China, in December 2019.

read more
What’s next?

12/05/2019 Diseases will not give up or disappear. Luckily, neither will science nor researchers. Just as they didn’t in the 1980s when the needle and the syringe were the only known way of injecting insulin, or in the 1990s when HIV meant a death penalty, or in the 2000s when destroying the cancer cells also affected the healthy cells.

What would it mean to slow down the beginning of Alzheimer’s disease? Could antibodies slow down our resistance to antibiotics and help overcome bacterial infections? What cell therapies would it take to avoid having aggressive chemotherapy ever again? And is there potential for gene therapy to reduce the toll of lifelong treatment?

read more

Campaigns

#WeWontRest in the fight against COVID-19

As the impact of COVID-19 continues to be felt across the world, the biopharmaceutical industry in Europe remains committed to global efforts to care for those affected, contain the outbreak and develop resources to tackle future outbreaks.

ARPharM member companies are working around the clock to find vaccines, diagnostics and treatments and ensure patients get access to the medicines they need.

Worldwide, there are more than 100 vaccine candidates in development and over 600 clinical trials underway to find a treatment to use in the fight against COVID-19.

read more

Togehter For More Health

We have launched the Together for More Health initiative because we all need a sustainable and efficient health system focused on the health and the specific health needs of the individual.

How shall we achieve the goals of the initiative?

Paying attention to policies and investments in the health sector through the eyes of the main industries involved and for the benefit of health of the individual.

We strive to attract more investment in the health sector, to create more value for society, to support health policies that lead to increased productivity and increase the well-being of people and society as a whole!

We strive to bring as much HEALTH as possible!

read more

#WeWontRest

We were born to end patients’ suffering.

To extend life and improve its quality.

That’s why in the 70s, when infectious diseases passed from person to person, we didn’t rest.

In the 80s, when a needle and syringe was the only option for insulin injection, we didn’t rest.

In the 90s, when contracting HIV was a death sentence, we didn’t rest.

In the 2000s, when killing cancer cells damaged healthy cells too, we didn’t rest.

And right now, after decades of tireless medical innovation, we still won’t rest.

read more

Members of the Association